QDPR deficiency drives immune suppression in pancreatic cancer

Area of Science:

• Biochemistry
• Immunology
• Oncology

Background:

• Immune checkpoint blockade (ICB) therapy efficacy is limited in some cancers.
• The role of biopterin metabolism in ICB resistance is not well understood.

Purpose of the Study:

• To investigate the role of biopterin metabolism in pancreatic ductal adenocarcinoma (PDAC) resistance to ICB therapy.
• To explore therapeutic strategies targeting biopterin metabolism to enhance ICB response.

Main Methods:

• Analysis of quinoid dihydropteridine reductase (QDPR) deficiency and its impact on biopterin metabolites (BH4, BH2).
• Assessment of reactive oxygen species (ROS) generation and H3K27me3 distribution.
• Evaluation of myeloid-derived suppressor cell (MDSC) recruitment and CXCR2 signaling.
• Testing the efficacy of BH4 supplementation in preclinical models of PDAC.

Main Results:

• QDPR deficiency in PDAC leads to BH2 accumulation and reduced BH4/BH2 ratio, increasing ROS.
• Reduced BH4/BH2 ratio decreases H3K27me3 at the CXCL1 promoter, promoting MDSC recruitment and ICB resistance.
• BH4 supplementation restores BH4/BH2 ratio, enhances anti-tumor immunity, and overcomes ICB resistance in QDPR-deficient PDAC.
• Lower QDPR expression correlates with decreased ICB responsiveness.

Conclusions:

• Biopterin metabolism, specifically the BH4/BH2 ratio regulated by QDPR, is a key determinant of ICB resistance in PDAC.
• BH4 supplementation represents a promising therapeutic strategy to improve ICB effectiveness in PDAC patients with deficient biopterin metabolism.
• These findings provide a basis for patient selection and combination therapy approaches to enhance ICB treatment outcomes.